Background—Microalbuminuria is associated with cardiovascular disease (CVD) mortality, but whether lower levels of urine albumin excretion similarly predict CVD is uncertain. We investigated associations between urine albumin:creatinine ratio (UACR) <30 mg/g, and incident hypertension, incident diabetes mellitus, and all-cause and CVD mortality, during a maximum of 11 years of follow-up.

Methods and Results—Individuals (37 091) in a health screening program between 2002 and 2012 with baseline measurements of UACR were studied. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for incident hypertension, incident diabetes mellitus, and mortality outcomes (lowest UACR quartile as reference) at follow-up. For linear risk trends, the quartile rank was used as a continuous variable in regression models. Nine-hundred sixty-three cases of incident hypertension, 511 cases of incident diabetes mellitus, and 349 deaths occurred during follow-up. In the fully adjusted models, there was a significant HR for the association between UACR and incident hypertension (highest UACR quartile HR 1.95 [95% CI 1.51, 2.53], P-value for trend across UACR quartiles P<0.001). In contrast, the association between UACR and incident diabetes mellitus was not significant (highest UACR quartile, HR 1.15 [95% CI 0.79, 1.66], P-value for trend P=0.20). For CVD mortality, with increasing UACR quartiles, there was a significant increase in HR across quartiles, P=0.029, (for all-cause mortality, P=0.078).

Conclusions—Low levels of albuminuria, UACR below 30 mg/g, are associated with increased risk of incident hypertension and CVD mortality at follow-up, but are not associated with increased risk of incident diabetes mellitus. (J Am Heart Assoc. 2016;5: e003245 doi: 10.1161/JAHA.116.003245)

Key Words: albuminuria • cardiovascular disease risk factors • diabetes mellitus • hypertension • low-grade albuminuria • microalbuminuria heart failure • mortality

Chronic kidney disease is a costly disease, and the costs associated with the care of patients with end-stage renal disease are estimated to exceed US$1 trillion globally.¹

Albinurina or microalbuminuria, albumin excretion rate ≥30 mg/24 hours or albumin/creatinine ratio (ACR) ≥30 mg/g (≥3 mg/mmol), is used as a marker of renal damage and is used to define chronic kidney disease along with low estimated glomerular filtration rate (eGFR).² Albuminuria is not only a predictor of development and progression of diabetic³ and nondiabetic⁴ renal diseases, but is a marker of endothelial dysfunction.⁵ In 1969, Keen and colleagues first showed that increased urinary albumin excretion (microalbuminuria) occurred in people with type 2 diabetes mellitus compared with controls during an oral glucose tolerance test.⁶

A recent meta-analysis based on more than 100 000 individuals with ACR data and 1.1 million participants with dipstick data from 21 general population cohorts demonstrated that albuminuria was associated with all-cause and cardiovascular mortality independently of each other and traditional cardiovascular risk factors.⁷ These data from 21 studies from 14 countries of Asia, Europe, North America, and Oceania showed consistency in both continuous and categorical models for ACR across the different regional cohorts.
Both cardiovascular disease (CVD) and diabetes mellitus share many risk factors in common (the “common soil” hypothesis), but whether urine albumin:creatinine ratio (UACR) below 30 mg/g similarly predicts mortality outcomes, hypertension, and diabetes mellitus in the same population is uncertain. It is well established that microalbuminuria is associated with all-cause and cardiovascular mortality, and microalbuminuria is associated with diabetes mellitus and resistant hypertension. However, although it has been shown that urinary albumin excretion predicts blood pressure progression in people without diabetes mellitus or hypertension, at levels of UACR below 30 mg/g, it is less certain whether these levels are associated with CVD mortality, and increased risk of incident hypertension and incident diabetes mellitus.

The aim of the study was to test the hypothesis that UACR below 30 mg/g was associated with the following outcomes: incident hypertension, incident diabetes mellitus, and all-cause and CVD mortality during a maximum of 11 years of follow-up, in a middle-aged relatively healthy occupational cohort with exclusion of those with UACR >30 mg/g.

Methods
Study Population
The study population consisted of individuals who participated in a comprehensive health screening program with UACR at Kangbuk Samsung Hospital, Seoul, Korea from 2002 to 2012 (N=44 964). The purpose of the screening program was to promote health through early detection of chronic diseases and their risk factors. Additionally, the Korean Industrial Safety and Health Law demands that working individuals participate in an annual or biennial health examination. Participants, who were employees or spouses of companies or local governmental organizations, registered individually for the program. For this analysis, we opportunistically investigated associations between low levels of albuminuria (below the threshold for defining microalbuminuria), and risks of incident hypertension, incident diabetes mellitus, and CVD mortality at follow-up. Incident hypertension was defined by the presence of new antihypertensive medication, self-reporting by the patient of hypertension, and a blood pressure at follow-up ≥140/90 mm Hg; incident diabetes mellitus was defined by new antidiabetic medication, self-reporting by the patient of diabetes mellitus, or a fasting glucose at follow-up ≥126 mg/dL. Subjects were excluded for 1 or more of the following reasons: UACR ≥30 mg/g, subjects with missing data for smoking, alcohol, or exercise at baseline; subjects with a history of cancer; and subjects with unknown mortality status. The total number of eligible subjects for testing associations with all-cause and CVD mortality was 37 091 (median follow-up [FU]: 5.13 years and mean [SD] FU: 4.99 [2.57] years). To test the effect of low-grade albuminuria for incident type 2 diabetes mellitus and hypertension, we studied 13 475 subjects who had baseline UACR and follow-up data on more than 1 occasion between 2002 and 2013. To analyze associations between UACR and incident hypertension, we additionally excluded the following: subjects with missing data for smoking, alcohol, or exercise at baseline; and subjects with hypertension at baseline; thus, the total number of eligible subjects for this analysis was 9102 (median FU: 2.68 years and mean [SD] FU: 3.52 [2.13] years). For testing associations between UACR and incident diabetes mellitus, data were available on 10 930 subjects (median FU: 2.98 years and mean [SD] FU: 3.47 [2.17]) years after excluding subjects for missing data and subjects with type 2 diabetes mellitus at baseline.

This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital. Requirement for informed consent was waived as de-identified information was retrieved retrospectively.

Measurements
As part of the health screening program, individuals completed questionnaires related to their medical and social history and medication use. Individuals were asked about duration of education (years), frequency of exercise (none, less than once a week, at least once a week, ≥3 times per week [regular exercise]), smoking history (never, former, or current), and alcohol consumption (g/week).

Trained staff also collected anthropometric measurements and vital statistics. Body weight was measured in light clothing with no shoes to the nearest 0.1 kg using a digital scale. Height was measured to the nearest 0.1 cm. Body mass index was calculated as weight in kilograms divided by height in meters squared. Blood pressure was measured using standard mercury sphygmomanometers. Blood samples were collected after at least 10 hours of fasting and were analyzed in the same core clinical laboratory. The core clinical laboratory has been accredited and participates annually in inspections and surveys by the Korean Association of Quality Assurance for Clinical Laboratories.

Urinary albumin excretion was measured from an early-morning urine sample as the UACR. The urinary albumin concentration was determined by immunoradiometry (radioimmunological competition assay; Immunotech) and immunoturbidimetric assay (Roche Modular P800), and urinary creatinine concentration was measured by a modified Jaffe method. The UACR measured in a spot urine sample is highly correlated with the 24-hour urine albumin excretion. All subjects with a UACR ≥30 mg/g were excluded from these analyses.
Ascertainment of Mortality

Deaths among participants were identified by matching the information to death records from the National Statistical Office using identification numbers assigned to subjects at birth. Causes of death were coded centrally by trained coders using the ICD-10 classification (International Classification of Diseases, 10th revision) and ICD 00-99 was considered to represent cardiovascular death.

Statistical Analyses

The statistical analysis was performed using STATA version 11.2 (StataCorp LP, College Station, TX). Reported *P*-values were 2-tailed, and <0.05 were considered statistically significant. The distribution of continuous variables was evaluated and transformations were conducted for nonparametric variables. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for mortality in each quartile, compared with the lowest quartile as reference for urine ACR. For testing linear risk trends, we used each quartile, compared with the lowest quartile as reference to estimate hazard ratios (HRs) and 95% CIs for mortality in metric variables. Cox proportional hazards models were used.

Results

The baseline characteristics of the cohort according to death, CVD death, incident hypertension, and incident diabetes mellitus at follow-up are shown in Table 1. There were 349 deaths during follow-up and blood pressure and the proportion of subjects with hypertension and diabetes mellitus was higher in subjects who died during follow-up. UACR was increased at baseline in subjects who died during follow-up. To investigate associations between increasing UACR and risk factors for all-cause and cardiovascular mortality, we examined the trends across UACR quartiles and risk factors for all-cause and cardiovascular mortality. Table 2 shows the baseline characteristics of the cohort according to baseline UACR quartiles. Quartiles of UACR were for quartile 1: <3.4 mg/g (0.38 mg/mmol); quartile 2: 3.4 to 4.7 mg/g (0.38–0.53 mg/mmol); quartile 3: 4.7 to 7.4 mg/g (0.53–0.84 mg/mmol), and for the highest quartile ≥7.4 mg/g (0.84 mg/mmol). There was a significant increase in the proportion of people with diabetes mellitus, obesity, and hypertension across UACR quartiles. There were remarkably similar eGFR values across UACR quartiles, with eGFR varying by only 0.4 mL/min across UACR quartiles.

We investigated associations between baseline UACR quartiles and all-cause and CVD mortality. Table 3 shows the HRs for the associations between UACR quartiles and all-cause and CVD mortality. The fully adjusted models showed a significant trend with increasing UACR quartiles and CVD mortality. Adjustment for eGFR in these models had an impact on the strength of the association between UACR and all-cause mortality. Before adjustment for eGFR, there was a significant trend for the association between UACR and all-cause mortality, *P*=0.036, whereas after adjustment for eGFR, there was a decrease in the strength of the association between UACR and all-cause mortality, *P*=0.078.

As can be seen for CVD mortality with each increasing quartile of UACR, there was an increase in the HR for CVD mortality relative to Quartile 1, HR=1; Quartile 2, HR=1.45; Quartile 3, HR=2.05; Quartile 4, HR=3.38, *P*-value for the trend across increasing quartiles *P*=0.029.

Next we tested associations between baseline UACR and CVD mortality (Figure 1) and baseline UACR and all-cause mortality (Figure 2) in clinically relevant subgroups. These analyses investigated trends across UACR quartiles and interaction between subgroup and UACR. For CVD mortality there were significant interactions with age and vigorous exercise. For all-cause mortality no significant interactions with UACR were noted.

We investigated associations between baseline UACR and both incident hypertension and incident diabetes mellitus at follow-up. In the fully adjusted models there was a significant HR for the association between UACR and incident hypertension (highest UACR quartile HR 1.95 [95% CI 1.51, 2.53] and the *P*-value for the trend across UACR quartiles was *P*=0.001) (Table 4). In contrast, in the fully adjusted models there was a nonsignificant HR for the association between UACR and
Table 1. Baseline Characteristics of the Cohort According to Vital and Disease Status at Follow-Up

| Baseline Characteristics | Overall | No Death | New Death | P-Value | No CVD Death | New CVD Death | P-Value | No Incident Hypertension | Incident Hypertension | P-Value | No Incident Diabetes Mellitus | Incident Diabetes Mellitus | P-Value |
|--------------------------|---------|----------|-----------|---------|--------------|---------------|---------|--------------------------|-----------------------|---------|----------------------------|--------------------------|---------|
| Total number             | 37,091  | 37,091   | 37,091    |         | 37,091       | 37,091        |         | 9102                     | 9102                  |         | 10,930                     | 10,930                   |         |
| Number of event          | 37,091  | 36,742   | 349       |         | 37,041       | 50            |         | 8139                     | 963                   |         | 10,419                     | 511                       |         |
| N (%) Men                | 19,688  | 19,437   | 251       |         | 19,652       | 36 (72.0)     |         | 4187 (51.4)              | 665 (89.1)            |         | 5768 (55.4)               | 360 (70.5)               |         |
| Age, y                   | 45.8    | 45.7     | 57.2      | -0.001  | 45.8 (11.9)  | 58.9 (12.6)   | -0.001  | 42.1 (10.1)              | 47.6 (10.2)           | -0.001  | 43.7 (10.6)               | 49.6 (9.6)               | -0.001  |
| BMI, kg/m²               | 23.6    | 23.6     | 23.9      | 0.0109  | 23.6 (3.2)   | 24.0 (3.6)    | 0.0402  | 23.0 (2.9)               | 24.6 (2.9)            | -0.001  | 23.4 (3.0)               | 25.3 (2.8)               | -0.001  |
| Systolic BP, mm Hg       | 115.9   | 115.9    | 123.6     | -0.001  | 115.9 (14.9) | 127.4 (18.8)  | -0.001  | 110.4 (10.8)            | 119.1 (9.9)           | -0.001  | 114.7 (14.0)             | 121.8 (14.4)             | -0.001  |
| Diastolic BP, mm Hg      | 74.9    | 74.9     | 78.5      | -0.001  | 74.9 (9.3)   | 81.2 (10.7)   | -0.001  | 71.6 (7.3)              | 77.5 (6.7)            | -0.001  | 74.5 (9.7)               | 79.2 (9.4)               | -0.001  |
| Higher education (%)*    | 11,046  | 10,964   | 82 (35.2) | -0.001  | 11,034 (55.8)| 12 (35.3)     | 0.016   | 2927 (70.4)             | 316 (55.2)            | -0.001  | 3710 (67.3)              | 134 (47.9)               | -0.001  |
| Regular exercise (%)†    | 7183    | 7122     | 61 (17.5) | 0.370   | 7177 (19.4)  | 6 (12.0)      | 0.187   | 1475 (18.1)             | 213 (22.1)            | 0.003   | 1988 (19.1)              | 114 (22.3)               | 0.071   |
| Current smoker (%)       | 9774    | 9654     | 120 (34.4)| 0.001   | 9758 (26.3)  | 16 (32.0)     | 0.364   | 211 (25.9)              | 289 (30.0)            | 0.007   | 2674 (25.7)              | 163 (31.9)               | 0.002   |
| Alcohol intake ≥20 g/day (%) | 7542    | 7457     | 85 (24.4)| 0.061   | 7533 (20.3)  | 9 (18.0)      | 0.682   | 1459 (17.9)             | 272 (28.3)            | -0.001  | 2076 (19.9)              | 170 (33.3)               | -0.001  |
| Fatty liver (%)          | 10,882  | 10,784   | 98 (28.1)| 0.603   | 10,865 (29.3)| 17 (34.0)     | 0.469   | 1960 (24.1)             | 378 (39.3)            | -0.001  | 2809 (27.0)              | 298 (58.5)               | -0.001  |
| Obesity (%)              | 11,691  | 11,569   | 122 (35.0)| 0.165   | 11,674 (31.5)| 17 (34.0)     | 0.706   | 1976 (24.3)             | 407 (42.3)            | -0.001  | 3064 (29.4)              | 271 (53.0)               | -0.001  |
| Hypertension (%)         | 8740    | 8594     | 146 (41.8)| -0.001  | 8714 (23.6)  | 26 (32.0)     | -0.001  | —                        | —                     | —       | —                         | —                        | —       |
| Diabetes mellitus (%)    | 2314    | 2254     | 60 (17.2)| -0.001  | 2305 (6.2)   | 9 (18.0)      | 0.001   | —                        | —                     | —       | 1323 (12.7)              | 1443 (23.9)              | <0.001  |
| Hx of CVD (%)            | 3016    | 2978     | 38 (10.9)| 0.058   | 37,041       | 9 (18.0)      | 0.011   | —                        | —                     | —       | 1323 (12.7)              | 1443 (23.9)              | <0.001  |
| Insulin, μIU/mL          | 8.01    | 8.01     | 8.23      | 0.0011  | 8.01 (6.27–10.26)| 8.32 (6.58–10.36) | 0.411   | 4.89 (3.1–6.73)         | 5.5 (4.01–8.03)       | 0.002   | 4.8 (3.17–6.85)          | 6.15 (4.1–8.71)          | 0.007   |
| Glucose, mg/dL           | 96.4    | 96.3     | 104.0     | -0.001  | 96.4 (17.8)  | 101.8 (22.8)  | 0.033   | 93.4 (13.6)             | 99.1 (18.6)           | -0.001  | 92.6 (8.7)               | 105.5 (10.9)             | <0.001  |
| Total cholesterol, mg/dL | 195.9   | 195.9    | 193.5 (37.9) | 0.202  | 195.9 (35.2) | 200.2 (26.7)  | 0.383   | 193.2 (33.7)            | 202.1 (35.2)          | -0.001  | 195.2 (34.1)             | 207.3 (35.7)              | -0.001  |
| LDL-C, mg/dL             | 115.6   | 115.6    | 111.0     | 0.006   | 115.6 (31.3) | 119.5 (22.9)  | 0.380   | 113.2 (30.0)            | 120.5 (31.7)          | -0.001  | 114.8 (30.4)             | 122.7 (32.8)              | -0.001  |
| HDL-C, mg/dL             | 55.7    | 55.7     | 55.0      | 0.017   | 55.7 (13.3)  | 55.2 (11.0)   | 0.767   | 56.9 (13.7)             | 54.2 (11.9)           | -0.001  | 56.5 (13.4)              | 51.8 (11.0)               | <0.001  |

Continued
Table 1. Continued

| Baseline Characteristics | Overall | No Death | New Death | P-Value | No CVD Death | New CVD Death | P-Value | No Incident Hypertension | Incident Hypertension | P-Value | No Incident Diabetes Mellitus | Incident Diabetes Mellitus | P-Value |
|-------------------------|---------|----------|-----------|---------|--------------|---------------|---------|--------------------------|----------------------|---------|-----------------------------|------------------------|---------|
| Triglycerides, mg/dL    | 103 (72–154) | 103 (72–154) | 114 (82–162) | <0.001 | 103 (72–154) | 117 (82–167) | 0.215 | 94 (67–140) | 122 (86–177) | <0.001 | 100 (70–148) | 152 (104–218) | <0.001 |
| HOMA IR                 | 1.86 (1.40–2.48) | 1.86 (1.40–2.48) | 2.05 (1.55–2.68) | <0.001 | 1.86 (1.40–2.48) | 2.05 (1.60–2.48) | 0.175 | 1.81 (1.36–2.34) | 2.04 (1.60–2.70) | <0.001 | 1.84 (1.40–2.37) | 2.42 (1.88–3.17) | <0.001 |
| eGFR, mL/min            | 81.6 (14.4) | 81.7 (14.4) | 76.6 (13.0) | <0.001 | 81.6 (14.4) | 72.9 (12.9) | <0.001 | 83.5 (14.4) | 78.5 (12.0) | <0.001 | 82.1 (14.2) | 77.5 (12.9) | <0.001 |

SI conversion factors (multiply the conversion factor to obtain SI unit): insulin, 6.945 (pmol/L); glucose, 0.0555 (mmol/L); total cholesterol, 0.0259 (mmol/L); LDL-C, 0.0259 (mmol/L); HDL-C, 0.0259 (mmol/L); triglycerides, 0.0113 (mmol/L). BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HOMA IR, homeostatic model assessment-insulin resistance; LDL-C, low-density lipoprotein cholesterol.

*College graduate.
†≥3 times per week.

Discussion

We show for the first time that UACR below 30 mg/g is associated with increased risk of hypertension and CVD mortality over 10 years of follow-up. Our results show that there was a linear trend for increased risk of incident hypertension and CVD mortality across UACR quartiles, and the HRs for the associations between UACR and each outcome were independent of eGFR levels. eGFR only varied by 0.4 mL/min across UACR quartiles, and the HRs for the associations between UACR and incident diabetes mellitus, with very low-grade albuminuria defined by UACR, and these trends were independent of eGFR levels. eGFR only varied by 0.4 mL/min across UACR quartiles, and the HRs for the associations between UACR and each outcome were independent of eGFR levels.

We show for the first time that UACR below 30 mg/g is associated with increased risk of hypertension and CVD mortality over 10 years of follow-up. Our results show that there was a linear trend for increased risk of incident hypertension and CVD mortality across UACR quartiles, and the HRs for the associations between UACR and each outcome were independent of eGFR levels. eGFR only varied by 0.4 mL/min across UACR quartiles, and the HRs for the associations between UACR and each outcome were independent of eGFR levels.
between UACR and increased cardiovascular morbidity and mortality with no threshold of UACR contributing to increased risk. These results are in keeping with our results and with our previous study in which we showed an association between different cardiovascular risk factors and low-grade albuminuria. However, the baseline characteristics of subjects in the present study were very different from the baseline characteristics of subjects in the present study. In these previous studies, there was inclusion of subjects with recognized cardiovascular risk factors at baseline, such as diabetes, hypertension with left ventricular hypertrophy, and coronary artery disease. Furthermore, baseline UACR was notably higher in these previous studies than in the presented data. Consequently, the presented data are novel and this is the first study to show that UACR below 30 mg/g is associated with increased risk of CVD mortality.

Why is low-grade albuminuria, UACR below 30 mg/g, associated with increased CVD mortality and incident hypertension? Increased albumin excretion is the net result of glomerular filtration and tubular resorption, and it is suggested that in normal physiological conditions there is little filtration. When irreversible increases in albumin excretion occur it is assumed that there is increased glomerular hydraulic pressure, increased glomerular filtration coefficient, and change in size and charge selectivity of the glomerular membrane. The mechanisms linking increased albuminuria and cardiovascular mortality are uncertain, but it is likely that increased urinary albumin excretion reflects widespread vascular endothelial cell dysfunction, and it is plausible that this might predispose to increased accumulation of atherogenic lipoproteins within the subendothelial cell space. Thus, increased albuminuria might reflect glomerular and/or systemic vascular endothelial dysfunction that precedes development of hypertension in humans. In previous cross-sectional studies, increased urinary albumin excretion was associated with increased blood pressure in subjects with

![Table 2. Baseline Characteristics of Study Subjects by UACR Quartile](image)

| Characteristics | Overall | Q1 (<3.4 mg/g) | Q2 (3.4–4.7 mg/g) | Q3 (4.7–7.4 mg/g) | Q4 (≥7.4 mg/g) | P for Trend |
|-----------------|---------|---------------|------------------|------------------|----------------|-------------|
| N=37,091        |         | 9273          | 9274             | 9272             | 9272           |             |
| Age, y          | 45.8 (11.9) | 42.6 (10.7)  | 44.5 (11.3)      | 46.6 (11.9)      | 49.5 (12.5)    | <0.001      |
| BMI, kg/m²      | 23.6 (3.2)  | 23.7 (2.9)    | 23.3 (3.0)       | 23.4 (3.2)       | 24.0 (3.5)     | <0.001      |
| Systolic BP, mm Hg | 115.9 (14.9) | 113.5 (12.5) | 113.7 (13.7)    | 115.8 (14.8)     | 120.7 (16.9)   | <0.001      |
| Diastolic BP, mm Hg | 74.9 (9.9)  | 73.8 (9.0)    | 73.7 (9.5)       | 74.8 (9.9)       | 77.5 (10.7)    | <0.001      |
| Higher education (%)† | 11,046 (55.7) | 3138 (68.3)  | 2893 (58.9)      | 2651 (52.7)      | 2364 (44.8)    | <0.001      |
| Regular exercise (%)† | 7,183 (19.4) | 1796 (19.4)  | 1798 (19.4)      | 1790 (19.3)      | 2392 (18.0)    | 0.925       |
| Current smoker (%) | 9,774 (26.4) | 3,566 (38.5) | 2,448 (26.4)     | 1,914 (20.6)     | 1,846 (19.9)   | <0.001      |
| Alcohol intake ≥20 g/day (%) | 7,542 (20.3) | 2,447 (26.4) | 1,865 (20.1)     | 1,535 (16.6)     | 1,695 (18.3)   | <0.001      |
| Obesity (%)     | 11,691 (31.5) | 2,881 (31.1) | 2,611 (28.2)     | 2,732 (29.5)     | 3,467 (37.4)   | <0.001      |
| Hypertension (%)| 8,740 (23.6) | 1,363 (14.8) | 1,708 (18.5)     | 2,180 (23.6)     | 3,489 (37.7)   | <0.001      |
| Diabetes mellitus (%) | 2,314 (6.2) | 246 (2.7)    | 378 (4.0)        | 551 (5.9)        | 1,139 (12.3)   | <0.001      |
| Hx of CVD (%)   | 3,016 (8.1)  | 593 (6.4)    | 732 (7.9)        | 810 (8.7)        | 881 (9.5)      | <0.001      |
| Insulin, μIU/mL | 8.01 (6.27–10.26) | 7.69 (5.8–9.83) | 8.0 (6.36–10.09) | 8.1 (6.4–10.34) | 8.29 (6.47–10.84) | <0.001 |
| Glucose, mg/dL  | 96.4 (17.8)  | 93.9 (11.6)  | 94.4 (14.6)      | 96.0 (16.8)      | 101.2 (24.6)   | <0.001      |
| Total cholesterol, mg/dL | 195.9 (35.2) | 193.6 (33.5) | 194.1 (34.2)     | 196.2 (35.4)     | 199.8 (37.3)   | <0.001      |
| LDL-C, mg/dL    | 115.6 (31.3) | 116.0 (30.1) | 114.2 (30.6)     | 114.8 (31.3)     | 117.5 (33.0)   | 0.001       |
| HDL-C, mg/dL    | 55.7 (13.3)  | 54.3 (12.8)  | 56.2 (13.3)      | 56.8 (13.7)      | 55.6 (13.4)    | <0.001      |
| Triglycerides, mg/dL | 103 (72–154) | 105 (75–152) | 99 (70–146)      | 99 (69–149)      | 111 (76–169)   | <0.001      |
| HOMA IR         | 1.87 (1.40–2.48) | 1.75 (1.29–2.31) | 1.84 (1.40–2.40) | 1.88 (1.43–2.49) | 2.01 (1.48–2.74) | <0.001      |
| eGFR, mL/min    | 81.6 (14.4)  | 81.7 (13.4)  | 81.6 (14.1)      | 81.8 (14.6)      | 81.4 (15.5)    | 0.309       |

SI conversion factors (multiply the conversion factor to obtain SI unit): insulin, 6.945 (pmol/L); glucose, 0.0555 (mmol/L); total cholesterol, 0.0259 (mmol/L); LDL-C, 0.0259 (mmol/L); HDL-C, 0.0259 (mmol/L); triglycerides, 0.0113 (mmol/L); BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HOMA IR, homeostatic model assessment-insulin resistance; Hx, history; LDL-C, low-density lipoprotein cholesterol; UACR, urine albumin: creatinine ratio.

*College graduate.
†≥3 times per week.
Table 3. Risk of All-Cause and CVD Mortality According to Baseline UACR Quartiles

| ACR Quartiles, mg/g | Person-Years | Number of Events | Mortality Rate (100 000 Person-Year) | Age-Sex Adjusted HR (95% CI) | Multivariate HR* (95% CI) |
|---------------------|--------------|-----------------|-------------------------------------|-----------------------------|--------------------------|
|                     |              |                 |                                     | Model 1                     | Model 2                  | Model 3                  | Model 4                  |
| All-cause mortality |              |                 |                                     |                             |                          |                          |                          |
| Q1 (<3.4 mg/g)      | 42 971.8     | 63              | 146.6                               | 1.00 (reference)            | 1.00 (reference)         | 1.00 (reference)         | 1.00 (reference)         |
| Q2 (3.4–4.7 mg/g)   | 47 491.7     | 67              | 141.1                               | 0.93 (0.66–1.32)            | 0.77 (0.49–1.20)         | 0.76 (0.49–1.18)         | 0.74 (0.48–1.15)         |
| Q3 (4.7–7.4 mg/g)   | 47 411.1     | 89              | 187.7                               | 1.13 (0.81–1.57)            | 1.05 (0.69–1.58)         | 1.04 (0.69–1.56)         | 0.99 (0.66–1.50)         |
| Q4 (≥7.4 mg/g)      | 47 135.7     | 130             | 275.8                               | 1.33 (0.97–1.83)            | 1.37 (0.93–2.03)         | 1.33 (0.89–1.98)         | 1.25 (0.83–1.86)         |
| P for trend         |              |                 |                                     | 0.025                       | 0.019                    | 0.036                    | 0.078                    |
| CVD mortality       |              |                 |                                     |                             |                          |                          |                          |
| Q1 (<3.4 mg/g)      | 42 971.8     | 7               | 16.3                                | 1.00 (reference)            | 1.00 (reference)         | 1.00 (reference)         | 1.00 (reference)         |
| Q2 (3.4–4.7 mg/g)   | 47 491.7     | 11              | 23.2                                | 1.35 (0.52–3.51)            | 1.42 (0.34–6.00)         | 1.40 (0.33–5.90)         | 1.45 (0.34–6.15)         |
| Q3 (4.7–7.4 mg/g)   | 47 411.1     | 10              | 21.1                                | 1.09 (0.41–2.94)            | 1.97 (0.51–7.61)         | 1.93 (0.50–7.50)         | 2.05 (0.53–7.96)         |
| Q4 (≥7.4 mg/g)      | 47 135.7     | 22              | 46.7                                | 1.89 (0.77–4.61)            | 3.46 (0.97–12.35)        | 3.14 (0.86–11.48)        | 3.38 (0.92–12.39)        |
| P for trend         |              |                 |                                     | 0.163                       | 0.020                    | 0.038                    | 0.029                    |

*Model 1: adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, education level; Model 2: Model 1 adjustments plus adjustment for BMI, hypertension, diabetes mellitus, and history of CVD; Model 3: Model 2 adjustments plus adjustment for eGFR; Model 4: Model 3 adjustments plus adjustment for HDL and LDL.

SI units for ACR: divided by 8.84, mg/mmol. ACR indicates albumin/creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; UACR, urine albumin/creatinine ratio.
hypertension\textsuperscript{17,18} and in the general population,\textsuperscript{19} suggesting that the increased level of urinary albumin excretion in the present study could be in part due to an increase in blood pressure below levels to diagnose hypertension.

Although CVD and diabetes mellitus share many risk factors in common (the “common soil” hypothesis\textsuperscript{8}) and as discussed above microalbuminuria occurs in people with diabetes mellitus and CVD, our data suggest a disconnect between diabetes and CVD, since in contrast to CVD mortality and hypertension, low-grade albuminuria was not significantly associated with any marked increase in incident diabetes mellitus. Thus, we suggest that these data lend credence to the notion that microalbuminuria/albuminuria occurs as a consequence of vascular dysfunction in diabetes mellitus.

Figure 1. Risk of CVD mortality according to subgroup and quartiles of ACR concentration. ACR indicates albumin/creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; Homa, homeostatic model assessment; OR, odds ratio.
| Variable                      | No.   | OR (95% CI)                  | p for interaction |
|-------------------------------|-------|-----------------------------|-------------------|
| **Men**                       |       |                             |                   |
| Q2                            | 19,688| 1.140 (0.72-1.80)           | 1.320 (0.84-2.06) |
| Q3                            |       | 1.500 (0.71-3.16)           | 1.380 (0.63-3.03) |
| Q4                            |       | 1.410 (0.62-2.81)           |                   |
| **Women**                     |       |                             |                   |
| Q2                            | 17,403| 0.840 (0.54-1.34)           | 1.050 (0.68-1.67) |
| Q3                            |       | 0.500 (0.30-0.85)           | 1.090 (0.59-2.08) |
| Q4                            |       | 1.440 (0.68-2.99)           |                   |
| **Age <50 years**             |       |                             |                   |
| Q2                            | 13,601| 0.540 (0.30-0.94)           | 1.120 (0.71-1.81) |
| Q3                            |       | 1.450 (0.81-2.58)           |                   |
| Q4                            |       | 1.520 (0.97-2.38)           |                   |
| **Age ≥ 50 years**            |       |                             |                   |
| Q2                            | 29,949| 0.700 (0.55-0.91)           |                   |
| Q3                            |       | 1.050 (0.70-1.60)           |                   |
| Q4                            |       | 1.370 (0.93-2.02)           |                   |
| **Alcohol < 20g/day**         |       |                             |                   |
| Q2                            | 7,542 | 0.800 (0.58-1.12)           |                   |
| Q3                            |       | 1.000 (0.82-1.22)           |                   |
| Q4                            |       | 1.270 (0.84-1.93)           |                   |
| **No or ever smoker**         | 27,317| 0.840 (0.47-1.5)            |                   |
| Q2                            |       | 1.060 (0.60-1.89)           |                   |
| Q3                            |       | 1.540 (0.90-2.62)           |                   |
| Q4                            |       | 0.990 (0.59-1.71)           |                   |
| **Current smoker**            | 9,774 | 0.620 (0.39-1.02)           |                   |
| Q2                            |       | 1.060 (0.63-1.81)           |                   |
| Q3                            |       | 1.040 (0.63-1.70)           |                   |
| Q4                            |       | 1.000 (0.59-1.71)           |                   |
| **Vigorous exercise < 3 time/week** | 29,949| 0.700 (0.53-1.00) | 0.213 |
| Q2                            |       | 1.070 (0.70-1.63)           |                   |
| Q3                            |       | 0.800 (0.58-1.11)           |                   |
| Q4                            |       | 0.880 (0.57-1.37)           |                   |
| **Vigorous exercise ≥ 3 time/week** | 8,779 | 0.630 (0.49-1.05) | 0.213 |
| Q2                            |       | 0.950 (0.63-1.48)           |                   |
| Q3                            |       | 1.180 (0.72-2.01)           |                   |
| Q4                            |       | 1.130 (0.70-1.84)           |                   |
| **< college graduate**        | 11,046| 0.950 (0.69-1.36)           |                   |
| Q2                            |       | 1.080 (0.72-1.68)           |                   |
| Q3                            |       | 1.350 (0.90-2.02)           |                   |
| Q4                            |       | 1.340 (0.90-2.01)           |                   |
| **≥ college graduate**        |       |                             |                   |
| Q2                            | 26,205| 0.690 (0.48-1.05)           |                   |
| Q3                            |       | 0.990 (0.69-1.46)           |                   |
| Q4                            |       | 1.350 (0.85-2.17)           |                   |
| **No Fatty liver**            |       |                             |                   |
| Q2                            | 10,882| 1.080 (0.65-1.77)           |                   |
| Q3                            |       | 1.350 (0.84-2.17)           |                   |
| Q4                            |       | 1.560 (0.95-2.53)           |                   |
| **Fatty liver**               |       |                             |                   |
| Q2                            | 38,324| 0.500 (0.14-1.73)           |                   |
| Q3                            |       | 1.300 (0.54-3.28)           |                   |
| Q4                            |       | 1.390 (0.54-3.89)           |                   |
| **eGFR % < 90/ml/min**        |       |                             |                   |
| Q2                            | 8,767 | 0.600 (0.50-1.38)           |                   |
| Q3                            |       | 1.120 (0.71-1.74)           |                   |
| Q4                            |       | 1.250 (0.80-1.94)           |                   |
| **eGFR % ≥ 90/ml/min**        |       |                             |                   |
| Q2                            | 1,135 | 0.770 (0.49-1.24)           |                   |
| Q3                            |       | 0.770 (0.49-1.24)           |                   |
| Q4                            |       | 1.260 (0.83-1.94)           |                   |
| **eGFR % < 60/ml/min/cc**     |       |                             |                   |
| Q2                            | 35,956| 0.810 (0.53-1.32)           |                   |
| Q3                            |       | 0.980 (0.63-1.68)           |                   |
| Q4                            |       | 1.380 (0.90-2.11)           |                   |
| **eGFR % ≥ 60/ml/min/cc**     |       |                             |                   |
| Q2                            | 34,776| 0.830 (0.53-1.32)           |                   |
| Q3                            |       | 0.890 (0.65-1.31)           |                   |
| Q4                            |       | 1.380 (0.90-2.11)           |                   |
| **No diabetes**               |       |                             |                   |
| Q2                            | 2,314 | 0.180 (0.02-1.17)           |                   |
| Q3                            |       | 1.560 (0.41-5.86)           |                   |
| Q4                            |       | 1.260 (0.35-4.50)           |                   |
| **diabetes**                  |       |                             |                   |
| Q2                            | 28,315| 0.700 (0.42-1.17)           |                   |
| Q3                            |       | 1.060 (0.66-1.68)           |                   |
| Q4                            |       | 1.550 (0.98-2.43)           |                   |
| **Homa < 75%ile**             |       |                             |                   |
| Q2                            | 8,773 | 0.960 (0.37-2.51)           |                   |
| Q3                            |       | 1.070 (0.43-2.48)           |                   |
| Q4                            |       | 0.980 (0.40-2.38)           |                   |
| **Homa ≥ 75%ile**             |       |                             |                   |
| Q2                            | 25,399| 0.860 (0.50-1.48)           |                   |
| Q3                            |       | 1.030 (0.61-1.76)           |                   |
| Q4                            |       | 1.750 (0.86-3.60)           |                   |
| **BMI ≤ 25 kg/m^2**           |       |                             |                   |
| Q2                            | 11,691| 0.610 (0.28-1.31)           |                   |
| Q3                            |       | 1.010 (0.52-1.97)           |                   |
| Q4                            |       | 0.900 (0.47-1.73)           |                   |

Figure 2. Risk of all-cause mortality according to subgroup and quartiles of ACR concentration. ACR indicates albumin/creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; Homa, homeostatic model assessment; OR, odds ratio.
rather than albuminuria/vascular dysfunction being a causal factor in the pathogenesis of diabetes mellitus.

Our study does have some limitations that should be discussed. UACR measurement was only available from a single measurement and since UACR can vary from day to day, this will result in imprecision in the UACR measurement. Moreover, although the absolute variability in ACR decreases with the magnitude of albuminuria, on the other hand a percentage of baseline ACR variability increases. However, there is a considerable amount of evidence showing that a single voided test is reliable and useful in screening for disease and follow-up of patients, and this methodology avoids the problems associated with a 24-hour urine collection. Despite the potential imprecision associated with a single voided measurement of UACR, we have studied a large number of subjects in this cohort and any imprecision in the measurement of UACR would bias results towards the null.

Although our subjects predominantly have normal renal function, it is possible that eGFR values are underestimated since it is known that the MDRD Study equation underestimates measured GFR when GFR is ≥60 mL/min per 1.73 m² in healthy individuals. Furthermore, it is possible that development of diabetes mellitus or hypertension during follow-up has influenced our results, although our study design has limited this possibility by exclusion of these subjects at baseline. Although the follow-up time was a little different for studying the associations between baseline UACR and incident diabetes mellitus and incident hypertension, compared to studying associations with mortality outcomes, it should be noted that there were similar associations between baseline UACR and incident hypertension and CVD mortality, in contrast to the (lack of an) association between baseline UACR and incident diabetes mellitus. Thus, it seems unlikely that the shorter period of

### Table 4. Risk of Incident Hypertension According to Baseline ACR Quartiles

| ACR Quartiles, mg/g | Person-Years | Number of Events | Incidence Rate (1000 Person-Years) | Age-Sex Adjusted HR (95% CI) | Multivariate HR*(95% CI) |
|---------------------|--------------|-----------------|-----------------------------------|-----------------------------|-------------------------|
|                     |              |                 |                                    |                             | Model 1 | Model 2 | Model 3 | Model 4 |
| N=9102              |              |                 |                                    |                             | Model 1 | Model 2 | Model 3 | Model 4 |
| Q1 (<3.4 mg/g)      | 7171.4       | 167             | 23.3                               | 1.00 (reference)            | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Q2 (3.4–4.7 mg/g)   | 7657.3       | 198             | 25.9                               | 1.33 (1.08–1.64)            | 1.23 (0.93–1.63) | 1.17 (0.88–1.55) | 1.18 (0.89–1.56) | 1.17 (0.89–1.56) |
| Q3 (4.7–7.4 mg/g)   | 7655.3       | 241             | 31.5                               | 1.72 (1.40–2.11)            | 1.61 (1.23–2.12) | 1.46 (1.11–1.92) | 1.48 (1.12–1.94) | 1.50 (1.14–1.97) |
| Q4 (≥7.4 mg/g)      | 7134.9       | 357             | 50.0                               | 2.54 (2.10–3.08)            | 2.42 (1.88–3.13) | 1.94 (1.50–2.50) | 1.95 (1.51–2.53) | 1.97 (1.52–2.55) |

*Model 1: adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, and education level; Model 2: Model 1 plus adjustment for SBP and BMI; Model 3: Model 2 plus adjustment for eGFR; Model 4: model 3 adjustments plus adjustment for HDL and LDL.

### Table 5. Risk of Incident Diabetes Mellitus According to Baseline ACR Quartiles

| ACR Quartiles, mg/g | Person-Years | Number of Events | Incidence Rate (1000 Person-Years) | Age-Sex Adjusted HR (95% CI) | Multivariate HR*(95% CI) |
|---------------------|--------------|-----------------|-----------------------------------|-----------------------------|-------------------------|
|                     |              |                 |                                    |                             | Model 1 | Model 2 | Model 3 | Model 4 |
| N=10,930            |              |                 |                                    |                             | Model 1 | Model 2 | Model 3 | Model 4 |
| Q1 (<3.4 mg/g)      | 9064.2       | 100             | 11.0                               | 1.00 (reference)            | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Q2 (3.4–4.7 mg/g)   | 9754.9       | 106             | 10.9                               | 1.07 (0.81–1.41)            | 1.01 (0.68–1.51) | 0.83 (0.56–1.25) | 0.83 (0.55–1.24) | 0.84 (0.56–1.26) |
| Q3 (4.7–7.4 mg/g)   | 9792.8       | 130             | 13.3                               | 1.33 (1.02–1.74)            | 1.52 (1.05–2.20) | 1.06 (0.73–1.55) | 1.05 (0.72–1.53) | 1.03 (0.71–1.51) |
| Q4 (≥7.4 mg/g)      | 9337.3       | 175             | 18.7                               | 1.70 (1.32–2.20)            | 1.83 (1.28–2.62) | 1.16 (0.81–1.68) | 1.15 (0.79–1.66) | 1.14 (0.78–1.64) |

*Model 1: adjustment for age, sex, center, year of screening examination, smoking status, alcohol intake, regular exercise, education level; Model 2: Model 1 plus adjustment for glucose, family history of diabetes mellitus and BMI; Model 3: Model 2 plus adjustment for eGFR; Model 4: Model 3 adjustments plus adjustment for HDL and LDL.

SI units for ACR: divided by 8.84, mg/mmol. ACR indicates albumin/creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; SBP, systolic blood pressure.
follow-up for incident diabetes mellitus has influenced our results.

In summary, our results show for the first time that in a young predominantly healthy occupational cohort, UACR below 30 mg/g is an independent risk factor for incident hypertension and CVD mortality during a maximum of 11 years of follow-up. In contrast, low-grade albuminuria was not a risk factor for incident diabetes during the same period of follow-up. Whether hypertension represents the intermediary causal link between UACR and increased CVD mortality is uncertain, as it is not possible to prove a causal link from this cohort study.

Acknowledgments
We acknowledge the efforts of the health screening group at Kangbuk Samsung Hospital, Korea.

Sources of Funding
Byrne is funded in part by the Southampton National Institute for Health Research Biomedical Research Centre. The work was support by the MRC-KHIDI UK-KOREA PARTNERING AWARD to CDB and KS (Medical Research Council MC_PC_16016).

Disclosures
None.

References
1. Wouters OJ, O’Donoghue DJ, Ritchie J, Kanavos PG, Narva AS. Early chronic kidney disease: diagnosis, management and models of care. Nat Rev Nephrol. 2015;11:491–502.
2. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, summary of recommendation statements. Kidney Int Suppl. 2013;3:5–14.
3. Nelson RG, Bennett PH, Beck GJ, Tan M, Kwiterovich PO, Rossing P. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med. 1996;335:1636–1642.
4. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1999;51:1908–1919.
5. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581–590.
6. Keen H, Chlouverakis C, Fuller J, Jarrett RJ. The concomitants of raised blood sugar: studies in newly-detected hyperglycaemics: II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Int J Epidemiol. 2014;43:11–15.
7. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–2081.
8. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes. 1995;44:369–374.
9. Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract. 2015;107:1–8.
10. Romero CA, Peixoto AJ, Orias M. Estimated GFR or albuminuria: which one is really associated with resistant hypertension? Semin Nephrol. 2014;34:492–497.
11. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426.
12. Wachtell K, Isaksen M, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Böevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansen K, Lederballe-Pedersen O, Nieminen MS, Oikin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901–906.
13. Sung KC, Kim BJ, Ryu S. An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. Atherosclerosis. 2008;196:320–326.
14. Ritz E. Albuminuria and vascular damage—the vicious twins. N Engl J Med. 2003;348:2349–2352.
15. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32:219–226.
16. Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena MG. Flow-mediated vasodilatation and the risk of developing hypertension in healthy post-menopausal women. J Am Coll Cardiol. 2004;44:1636–1640.
17. Hirayama A, Konta T, Hozawa A, Kawasaki R, Watanabe T, Shibata Y, Kayama T, Fukao A, Kubota J. Slight increase in urinary albumin excretion within the normal range predicts incident hypertension in a community-based Japanese population: the Takahata study. Hypertens Res. 2015;38:56–60.
18. Takase H, Sugira T, Otte N, Dohi Y. Urinary albumin as a marker of future blood pressure and hypertension in the general population. Medicine (Baltimore). 2015;94:e511.
19. Tanaka S, Takase H, Dohi Y, Kimura G. The prevalence and characteristics of microalbuminuria in the general population: a cross-sectional study. BMC Res Notes. 2013;6:265.
20. Chetana N, Andrew H, Alexander W, Jonathan C, Steven C. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis. 2013;62:1095–1101.
21. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis. 2006;47:1–7.
22. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309:1543–1546.
23. Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987;147:943–944.
24. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care. 1997;20:516–519.
25. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysyther AE, Zhang YL, Schmid CH, Levey AS. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18:2749–2757.